By CHAD BRAY
The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss drug maker Novartis as part of a swap of more than $20 billion in assets.
Published: June 2, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1nWYI51
from WordPress http://ift.tt/1olZ9V2
via Hadi Aboukhater
No comments:
Post a Comment